ICARE Social Media Post August 2023

 FDA Approval Post – Approves Niraparib 


A critical step forward in cancer care! The FDA has approved the use of niraparib and abiraterone acetate with prednisone in treating patients with BRCA-mutated castration-resistant prostate cancer. The green light comes backed by the robust efficacy data from the MAGNITUDE trial.

Read more about the FDA approval at ⁠

Learn more about the MAGNITUDE trial at

Permanent link to this article: https://inheritedcancer.net/post82423/